Table 1.
Antimicrobial Resistance in ESBL-producing E. coli from Blood (N = 15) and Urinary (N = 366)
| |
Susceptible (%) |
Intermediate (%) |
Resistant (%) |
|||
|---|---|---|---|---|---|---|
| Blood | Urine | Blood | Urine | Blood | Urine | |
| Amikacin |
11 (78.6) |
312 (86.4) |
2 (14) |
29 (8.0) |
1 (7.1) |
20 (5.5) |
| Gentamicin |
9 (60.0) |
254 (70.2) |
1 (7) |
3 (0.8) |
5 (33.3) |
105 (29.0) |
| Ciprofloxacin |
0 (0) |
62 (17.0) |
0 (0) |
1 (0.3) |
15 (100) |
302 (82.7) |
| Meropenem |
15 (100) |
- |
0 (0) |
- |
0 (0) |
- |
| Trimethoprim |
- |
68 (18.6) |
- |
0 (0) |
- |
297 (81.4) |
| Nalidixic Acid |
- |
43 (11.8) |
- |
1 (0.3) |
- |
319 (87.9) |
| Nitrofurantoin | - | 323 (88.5) | - | 20 (5.5) | - | 22 (6.0) |
Legend to Table 1. Susceptibility, Intermediate and Resistance to non-beta-lactam antimicrobial agents by Clinical Laboratory Standards Institute criteria for ESBL producing E. coli for the period July 2004 to December 2008. Note: one or more isolates had incomplete susceptibility data therefore the totals for each row do not fully correspond.